Hologic (NASDAQ:HOLX – Get Free Report) issued an update on its fourth quarter 2024 earnings guidance on Monday morning. The company provided earnings per share guidance of 0.970-1.040 for the period, compared to the consensus earnings per share estimate of 1.040. The company issued revenue guidance of $970.0 million-$985.0 million, compared to the consensus revenue estimate of $1.0 billion. Hologic also updated its FY 2024 guidance to 4.040-4.110 EPS.
Hologic Price Performance
Shares of HOLX traded up $1.01 during mid-day trading on Monday, hitting $79.64. 2,196,460 shares of the company traded hands, compared to its average volume of 1,618,592. Hologic has a one year low of $64.02 and a one year high of $81.00. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52. The business has a 50-day moving average of $74.56 and a 200 day moving average of $75.03. The stock has a market capitalization of $18.59 billion, a price-to-earnings ratio of 40.63, a PEG ratio of 2.62 and a beta of 0.99.
Hologic (NASDAQ:HOLX – Get Free Report) last released its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $0.98 by $0.05. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same period in the prior year, the firm earned $1.06 earnings per share. Hologic’s revenue was down .8% compared to the same quarter last year. As a group, equities analysts expect that Hologic will post 4.08 earnings per share for the current fiscal year.
Analyst Ratings Changes
View Our Latest Research Report on HOLX
Insider Buying and Selling
In related news, CEO Stephen P. Macmillan sold 3,672 shares of the firm’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the sale, the chief executive officer now directly owns 1,157,562 shares in the company, valued at $92,755,443.06. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the sale, the director now directly owns 45,472 shares in the company, valued at approximately $3,615,024. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the sale, the chief executive officer now owns 1,157,562 shares in the company, valued at $92,755,443.06. The disclosure for this sale can be found here. 1.75% of the stock is currently owned by company insiders.
Hologic Company Profile
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
See Also
- Five stocks we like better than Hologic
- Compound Interest and Why It Matters When Investing
- Survey: Top 175 Fittest Retirement Locations in America
- Overbought Stocks Explained: Should You Trade Them?
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- About the Markup Calculator
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.